48th week of 2017 patent applcation highlights part 8 |
Patent application number | Title | Published |
20170340520 | APPARATUS AND METHOD OF MANUFACTURING MULTI-COLUMN MULTI-MEDICINE ORAL DISSOLVING FILM - In an apparatus and method of manufacturing a multi-column multi-medicine oral dissolving film according to the present invention, all processes from film feeding, medicine coating, and medicine drying to product packaging are implemented as continuous automation processes, and under the automation processes, different kinds of medicines are coated on a base film in multiple columns in a signal layer by using a plurality of nozzles supplied with the different kinds of medicines, so that it is possible to improve productivity through the automation processes, to ensure product quality due to efficiency during drying caused by maintaining the thickness of the product, and to provide a convenience in the case of taking various kinds of small-amount medicines at one time or in the case of separately and selectively taking different kinds of medicines. | 2017-11-30 |
20170340521 | Clip-on nipple assembly - A clip-on nursing nipple assembly is disclosed which is readily portable by itself without being attached to a fluid supply and is adapted to be affixed to commonly sold water bottles or the like. The assembly has a funnel member with a nursing orifice at one end and a flanged base at the other. A skirt attached to the base forms a socket which fits over the spout of a commercially available water bottle or similar container. There is a clamping member which includes a funnel member engagement portion disposed on the funnel member, a jaw portion engageable on the spout of a water bottle, and a yoke portion connecting the funnel member engagement portion and the jaw portion and urging the base member into sealing engagement on the spout. | 2017-11-30 |
20170340522 | ACOUSTIC REFLECTOMETRY DEVICE IN CATHETERS - A device and method for verifying the proper position of catheters in the body by means of acoustic reflectometry, the device including a sound source, one or more sound receivers, a tube with compliant walls and open distal end to be introduced through an entrance to a body cavity, the sound source and receiver(s) coupled to the proximal end of the tube, a processor for causing the sound source to generate an acoustic excitation signal, the processor processing the acoustic signals sensed by the sound receiver(s) and generating an approximation of the acoustic impulse response of the tube, and the processor analyzing the acoustic impulse response to determine the position of the tube in the body cavity. | 2017-11-30 |
20170340523 | BIOMIMETIC MINERAL BASED ENDODONTIC CEMENT COMPOSITION AND USES THEREOF - Disclosed are biomimetic mineral based endodontic cement compositions. An endodontic cement comprises a paste A and a paste B. The paste A comprises a pozzolanic cementitious mineral paste and the paste B is a mixture comprising polyanionic polymers, phosphates, cement setting modulators, host-inclusion particles, bioactive glasses, and radiopacity agents suspended in a liquid carrier. | 2017-11-30 |
20170340524 | OXIDATIVE HAIR DYE COMPOSITION - An oxidative hair dye composition contains a first agent that includes an alkaline agent and is a cream formulation and a second agent that includes an oxidant and is liquid. The oxidative hair dye composition at the time of use has a viscosity at 25° C. of 3,000 to 10,000 mPa·s. The oxidative hair dye composition further includes (A) a salt of an oxidative dye, (B) a cationic surfactant in a content of 0.15% by mass or more, (C) a nonionic surfactant having an HLB value of 17 to 20, and (D) a nonionic surfactant having an HLB value of 11 or less. | 2017-11-30 |
20170340525 | Method of Reclaiming Formula Components of Antiperspirant Compositions - Methods for reclaiming formula components of an antiperspirant composition and recycling formula into its component parts for recycling into an antiperspirant composition. | 2017-11-30 |
20170340526 | DISPERSION AND METHOD FOR FORMING HYDROGEL - An object is to provide dispersion containing lipid peptide type compound useful as low molecular weight gelator, such as lipid dipeptide and lipid tripeptide, and dissolution accelerator capable of dissolving the lipid peptide type compound at lower temperature and more easily. It is also an object to provide dispersion that can form hydrogel by simpler method and under milder condition (low temperature) and from which gel can be obtained as gel having high thermal stability, and provide method for forming the gel. Dispersion including: a lipid peptide type compound in which peptide portion formed by repetition of at least two or more identical or different amino acids is bonded to lipid portion including C | 2017-11-30 |
20170340527 | BIODEGRADABLE MICROBEADS - An exfoliant composition including:
| 2017-11-30 |
20170340528 | APPARATUS AND PROCESS FOR FORMING PARTICLES - An apparatus and process for forming particles. The apparatus and process employs an intermediate mixer downstream of a batch mixer. | 2017-11-30 |
20170340529 | NEW CONTROLLED RELEASE ACTIVE AGENT CARRIER - The present invention relates to carriers for the controlled release of active agents, comprising surface reacted natural or synthetic calcium carbonate, one or more active agents, wherein said one or more active agent is associated with said surface-reacted calcium carbonate, and wherein said surface-reacted natural or synthetic calcium carbonate is a reaction product of natural or synthetic calcium carbonate with carbon dioxide and one or more acids, wherein the carbon dioxide is formed in situ by the acid treatment and/or is supplied from an external source. It further relates to the preparation of loaded carriers, as well as their use in different applications. | 2017-11-30 |
20170340530 | Indium Tin Oxide Coated Particles And Compositions - A solid or hollow particle ranging from 0.001 to 200 microns in diameter coated with Indium Tin Oxide (“ITO”) and a topical composition containing same as well as a method for protecting skin against IR radiation. | 2017-11-30 |
20170340531 | ODOR-REDUCING DEVELOPER FOR OXIDATION DYES - The aim of the present disclosure was to provide an improved oxidizing agent preparation for oxidative color modifying agents, which are present as soap based gels and contain ammonia as the alkalizing agent and optionally at least one oxidation dye precursor, and have a pH in the range of from 8 to 11.5, measured at 20° C., with which homogeneous and viscosity-stable application mixtures can be produced that release less ammonia during the entire leave-in time. It was surprisingly found that aqueous hydrogen peroxide preparations which contain selected 1-alkanols, glyceryl fatty acid esters, ethoxylated fatty alcohols, polyols and oils, achieve said aim in a very satisfactory manner. | 2017-11-30 |
20170340532 | METHODS AND COMPOSITIONS FOR WHITENING TEETH - Compositions and methods for whitening the teeth of a patient or subject are described for performing a dental prophylaxis or cleaning procedure during which at least one tooth whitening composition is applied to the surface of a stained tooth, said compositions and methods resulting in a tooth color change that is noticeable to the patient or subject immediately following the procedure. The novel procedure allows for a high degree of tooth whitening to be safely achieved in a short period of time while under the control of a dentist, dental hygienist, or other dental professional, and which at least partially coincides with the performance of a dental prophylaxis or cleaning procedure in order to save significant clinical operatory chair time compared to cleaning and whitening procedures that are performed in non-overlapping time frames or appointments. Light may also be used to enhance whitening. | 2017-11-30 |
20170340533 | Zinc Phosphate Complex - A soluble zinc polyphosphate complex made by combining ingredients which include an organic zinc salt and a plurality of long chain polyphosphates having 6 or more phosphate polymer units, the organic zinc salt and long chain polyphosphates being mixed in amounts that provide a phosphorus to zinc mole ratio of 15:1 to about 55:1. Further provided is a method of making this soluble zinc polyphosphate. | 2017-11-30 |
20170340534 | Zinc Phosphate Complex - An oral care composition having a soluble zinc polyphosphate complex made by combining ingredients including a zinc salt, a plurality of long chain polyphosphates having 6 or more phosphate polymer units, and a solvent, the relative amount of organic zinc salt and long chain polyphosphates provides a phosphorus to zinc mole ratio of at least 6:1. Further provided is a method of treating a subject suffering from dentinal sensitivity applying the oral care composition to the teeth and gums of the subject. | 2017-11-30 |
20170340535 | COMPOSITIONS AND METHODS FOR REMOVING HAIR STYLING AIDS - Disclosed are compositions for solubilizing and/or removing a hair styling aid composition from hair. The compositions comprise at least one active solvent, wherein the active solvent is a glycol or an ester; and a carrier composition comprising a liquid vehicle. Also disclosed are methods for solubilizing and/or removing hair styling aids from hair. | 2017-11-30 |
20170340536 | DYE COMPOSITION COMPRISING A PARA-PHENYLENEDIAMINE OXIDATION BASE, A NONIONIC SURFACTANT IN A MEDIUM RICH IN FATTY SUBSTANCES - The present invention relates to a composition for dyeing keratin fibres, in particular keratin fibres such as the hair, comprising: a) at least one oxidation base 3-(2,5-diaminophenyl)-1-propanol and/or acid salts thereof or solvates thereof such as hydrates; b) at least one coupler; c) at least 10% by weight of the total weight of the composition of a fatty substance which is preferably liquid and non-silicone-based; d) at least one nonionic surfactant chosen from alkyl(poly)glycoside surfactants, esters of oxyalkylenated sorbitan and fatty acids and oxyalkylenated fatty alcohols; e) optionally at least one basifying agent; and f) optionally at least one chemical oxidizing agent. The invention also relates to a process for dyeing keratin fibres such as the hair using the composition of the invention, and to a multi-compartment device for using the composition of the invention. | 2017-11-30 |
20170340537 | OXIDATIVE HAIR DYE COMPOSITION - An oxidative hair dye composition includes an alkaline agent and an oxidant. The oxidative hair dye composition further includes (A) α-naphthol in a content of 0.005 to 0.45% by mass, (B) at least one oily component selected from a higher alcohol, an ester, and a wax that are in a liquid state at 25° C., and (C) a nonionic surfactant having a polyoxyethylene chain having a number of moles of added ethylene oxide of 20 or more. | 2017-11-30 |
20170340538 | DYE COMPOSITION COMPRISING A PARA-PHENYLENEDIAMINE OXIDATION BASE, AN AMPHOTERIC SURFACTANT IN A MEDIUM RICH IN FATTY SUBSTANCES - The present invention relates to a composition for dyeing keratin fibres, in particular human keratin fibres such as the hair, comprising: a) at least one oxidation base 3-(2,5-diaminophenyl)-1-propanol and/or acid salts thereof or solvates thereof such as hydrates; b) at least one coupler; c) at least 10% by weight of the total weight of the composition of a fatty substance which is preferably liquid and non-silicone-based; d) at least one amphoteric surfactant; e) optionally at least one basifying agent; and f) optionally at least one chemical oxidizing agent. The invention also relates to a process for dyeing keratin fibres such as the hair using the composition of the invention, and to a multi-compartment device for using the composition of the invention. | 2017-11-30 |
20170340539 | Dentifrice Comprising Zinc-Amino Acid Complex - Disclosed herein are dentifrices comprising a zinc amino acid halide, which provide a precipitate of zinc oxide upon use with dilution with water and/or saliva. Methods of making and using the dentifrices are also provided. | 2017-11-30 |
20170340540 | COSMETIC COMPOSITION CONTAINING LINEAR OLEFIN SULFONATES, NON-OXYALKYLATED ANIONIC SURFACTANTS, AND NON-IONIC AND/OR AMPHOTERIC SURFACTANTS, AND COSMETIC TREATMENT METHOD - The invention relates to a cosmetic composition comprising:
| 2017-11-30 |
20170340541 | INTERNAL OLEFIN SULFONATE COMPOSITION - Provided are an internal olefin sulfonate composition which is capable of sufficiently enhancing foamability, foam dissipation property free from a slimy feeling during rinsing, and a feel after cleansing and subsequent drying, and a cleansing composition containing the same. | 2017-11-30 |
20170340542 | HAIR DYEING PROCESS USING AT LEAST ONE DYE, A TITANIUM SALT AND AN ANIONIC THICKENING POLYMER - The present invention relates to a process for dyeing keratin fibres, in particular human keratin fibres such as the hair, in which said fibres are treated using one or more cosmetic compositions comprising a) one or more dye(s), b) one or more titanium salts and b1) optionally at least one carboxylic acid, and c) one or more anionic thickening polymers derived from the polymerization of at least one monomer bearing an organic monoacid function, and d) optionally one or more chemical oxidizing agents such as hydrogen peroxide or one or more hydrogen peroxide-generating systems. | 2017-11-30 |
20170340543 | USE OF PARTICULAR PYRIDINIUM SALTS FOR THE TREATMENT OF KERATIN SUBSTANCES, COMPOSITIONS AND IMPLEMENTATION METHODS - The present invention relates to the use of one or more particular pyridinium salts for the treatment of keratin substances, particularly human keratin fibres such as hair. The invention also relates to a method for the treatment of keratin substances using said salts and optionally one or more chemical oxidizing agents. The invention also relates to a composition for lightening keratin substances comprising one or more pyridinium salts as defined hereinafter and one or more chemical oxidizing agents. The present invention also relates to one or more particular pyridinium salts and also to compositions containing them, especially compositions comprising a physiologically acceptable medium. | 2017-11-30 |
20170340544 | COSMETIC COMPOSITION FOR IMPROVING HEALTH OF SCALP AND METHOD OF PREPARING THE SAME - This invention relates to a cosmetic composition, which controls sebum secretion of the scalp to thus create an optimal environment for hair growth and activates growth factors for promoting hair strengthening and growth, thereby improving the health of the scalp. A method of preparing the same is also provided. In the cosmetic composition, an oligopeptide functions to create an environment suitable for hair growth by controlling the sebum secretion of the scalp, and also to activate growth factors that are effective at preventing hair loss by promoting hair growth through improvement of blood circulation in the scalp and by strengthening hair through hair follicle activity, thereby improving the health of the scalp and preventing hair loss. The oligopeptide of the invention can exhibit high safety and stability of use and high absorbability into the skin and is thus excellent in improving the health of the scalp, compared to the use of existing peptide compositions. | 2017-11-30 |
20170340545 | HAIR CARE COMPOSITIONS AND METHODS OF TREATING HAIR - The present invention provides compositions, kits and methods for treating scalp hair. The compositions include fluorinated (but not perfluorinated), non-polymeric compounds in a suitable excipient to provide beneficial effects on hair. | 2017-11-30 |
20170340546 | HAIR COSMETIC COMPOSITION - A hair cosmetic composition includes an alkaline agent and an oxidant, and is constituted as a hair dye or a hair bleaching/dye removing agent. The hair cosmetic composition further includes (A) a cellulose derivative and (B) a polyethylene glycol having a number average molecular weight of 2,000 or less. The mass ratio of the content of the (B) component to the content of the (A) component is 1 to 50. | 2017-11-30 |
20170340547 | AGENTS AND METHODS FOR THE TEMPORARY SHAPING OF KERATIN-CONTAINING FIBERS - The disclosure relates to a cosmetic product, comprising a) a cosmetic preparation, containing, in relation to its total weight, a | 2017-11-30 |
20170340548 | STABLE DISPERSIONS COMPRISING DROPS OF A PERFUMING AGENT - The present invention relates to the use of at least one cross-linked polymer or a cross-linked copolymer, the polymer or copolymer comprising at least one unit derived from the polymerization of one of the monomers selected from the group consisting of acrylic acid, methacrylic acid, alkyl acrylate comprising from 1 to 30 carbon atoms and salts thereof, for stabilizing at least one perfuming agent in a composition comprising at least 3% by weight of perfuming agent(s), the perfuming agent being in the form of dispersed drops in an aqueous gel, the aqueous gel comprising water, a buffer having a pKa comprised from 4.0 to 9.0 and a base, and the size of the perfuming agent drops ranging from 0.2 μm to 5,000 μm. | 2017-11-30 |
20170340549 | BLONDING AGENT AND METHOD FOR GENTLE OXIDATIVE HAIR LIGHTENING - A combination of at least one select dicarboxylic acid having 2 to 10 carbon atoms, in combination with at least one amino acid, selected from arginine, lysine, histidine or at least one of the salts of these amino acids, are included in a blonding powder to reduce the damage caused to keratin fibers by an oxidative bleaching treatment. | 2017-11-30 |
20170340550 | AGENTS AND METHODS FOR THE TEMPORARY SHAPING OF KERATIN-CONTAINING FIBERS - The disclosure relates to a cosmetic product, comprising a) a cosmetic preparation, containing, in relation to its total weight, a | 2017-11-30 |
20170340551 | EYELASH ORNAMENT COSMETIC - Provide is an eyelash ornament cosmetic characterized by containing at least a polymer emulsion, an extender and a viscosity regulator and controlling an average particle diameter of the extender to 1 μm more, wherein droplets put on the tips of eyelashes are dried and turned into fine spherical resin balls, and the tips of the eyelashes are ornamented to make it possible to provide the eyes with brilliantness and loveliness and further enhance stability of the quality. | 2017-11-30 |
20170340552 | Fan Masque - Fan Masque is a unique cosmetic paint formula. It is comprised of ingredients found in expensive spa facials that treat the skin, yet is formulated to look like paint, in bright sports team inspired colors. Fan Masque was specifically formulated to solve a the problem that my daughter and other young college women experienced. They could not fully engaging in super fan activities at events such as football games, because traditional face paints often cause skin breakouts and irritation. Fan Masque was designed to function as a face paint and facial all in one, made from only natural and organic ingredients. I experimented for months to find the right ingredients and proportions that make Fan Masque water resistant so it will not run in the rain, yet wash off easily with soap and water. It also contains a natural sunscreen which you do not find in traditional face paints or in spa treatment masks. Fan Mask is the first of a new product category thus needs patent protection for its novelty of use. It goes beyond being a face paint, that won't harm your skin, to one that actually benefits it. Every ingredient was carefully chosen for their already proven benefits to the skin. | 2017-11-30 |
20170340553 | PASTE-LIKE BLEACHING AGENT AND METHOD FOR GENTLE OXIDATIVE HAIR LIGHTENING - A combination of at least one selected dicarboxylic acid having 2 to 10 carbon atoms, in combination with at least one amino acid, selected from arginine, lysine, histidine or at least one of the salts of these amino acids, form a bleaching paste in order to reduce the damage to keratinic fibres caused by an oxidative bleaching treatment. | 2017-11-30 |
20170340554 | COSMETIC FORMULATION TO REDUCE FACIAL FLUSHING - The present invention features novel cosmetic skin care compositions for improving the appearance of flushed or rosacea-affected skin. | 2017-11-30 |
20170340555 | POST-BREW COFFEE GROUND PRODUCTS - Methods and systems to manufacture a soap bar comprising post-brew coffee particles are disclosed. A soap bar may comprise multiple post-brew coffee ground particle sizes to take advantage of the benefits associated with each size. For example, the soap bar may comprise espresso grinds (0.20 mm), regular grinds (1.0 mm), and/or coarse grinds (1.5 mm). A saponified fat base, e.g., a milk soap base, a plant oil base, and/or an animal fat base may be obtained and heated to a consistency. Collected post-brew coffee grounds may then be added. The coffee grounds may be anywhere from 1% to 65% of the total weight of the final product, depending on the desired soap quality. The final soap product may comprise coffee ground positive and coffee ground negative layers or portion, or the coffee grounds may be evenly dispersed throughout the product. | 2017-11-30 |
20170340556 | COMPOSITION COMPRISING BANYAN TREE, LOTUS, AND CLOVER SERUM FRACTIONS (HYPERPIGMENTATION) - The present invention relates to compositions comprising banyan tree, lotus, and clover serum fractions. A method of improving the appearance of a hyperpigmented spot may comprise the step of applying a composition comprising an effective amount of banyan tree serum fraction, lotus serum fraction, and clover serum fraction to a hyperpigmented spot on a skin surface, wherein the composition is applied for a period of time sufficient to improve the appearance of the hyperpigmented spot. The method may include the step of identifying a hyperpigmented spot on a facial skin surface. Other methods as disclosed include a method for improving the appearance of post-inflammatory hyperpigmentation. | 2017-11-30 |
20170340557 | SUBLINGUAL FENTANYL FORMULATIONS CONTAINING A PERMEATION ENHANCER - Sublingual formulations containing fentanyl, a pharmaceutically acceptable salt or ester thereof, ethanol, propylene glycol and menthol, as well as methods of treating pain by administering the formulations of the invention to a patient in need thereof. | 2017-11-30 |
20170340558 | HYDROPHILIC EXTERNAL GEL FORMULATION CAPABLE OF ENHANCING SKIN PERMEABILITY OF TACROLIMUS - The present invention relates to a formulation for external application to the skin containing tacrolimus, which is a poorly soluble drug used as a second therapeutic agent for atopic dermatitis and, more specifically, to a composition of a hydrophilic external gel formulation capable of enhancing skin permeability of tacrolimus, and a preparation method therefor. The hydrophilic external gel formulation loaded with tacrolimus of the present invention is in an easily preparable practical form with excellent moisturizing performance, and is excellent in spreadability and has improved drug delivery, skin permeability and skin residual capacity when applied to the skin, compared to conventional ointments, and thus can be usefully used for the treatment of atopic dermatitis and other immune diseases. | 2017-11-30 |
20170340559 | FORMULATIONS OF HUMAN TISSUE KALLIKREIN-1 FOR PARENTERAL DELIVERY AND RELATED METHODS - Provided are high concentration compositions of tissue kallikrein-1 (KLK1) and methods of parenterally administering such compositions to a subject in need thereof, where absorption into the circulation via, for example, intravenous or subcutaneous administration improves systemic pharmacokinetics, bioavailability, safety, and/or convenience relative to intravenous or other forms of administration. Also provided are recombinant human KLK1 (rhKLK1) polypeptides that can be readily concentrated to high protein concentrations, and substantially pure compositions thereof. | 2017-11-30 |
20170340560 | APPARATUS AND FORMULATIONS FOR SUPRACHOROIDAL DRUG DELIVERY - Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region. | 2017-11-30 |
20170340561 | ORAL COMPOSITION OF CELECOXIB FOR TREATMENT OF PAIN - The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib. | 2017-11-30 |
20170340562 | Cannabinoid caffeinated drinks, powder, beans, and cannabinoid loose tea leaf - This application discloses a caffeinated drink with cannabinoids, wherein the drink retains its original taste and appearance. This application also discloses coffee powder with cannabinoids, roasted coffee beans with cannabinoids, and loose tea leaf with cannabinoids. Methods to the make and use of the above caffeinated drinks, coffee powder, coffee beans, and loose tea leaf are also disclosed. | 2017-11-30 |
20170340563 | Methods for the Preparation of Liposomes Comprising Drugs - Provided herein are methods for preparing liposomes comprising increased concentration of hydrophobic therapeutic agents and improved stability, and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or inorganic salts. | 2017-11-30 |
20170340564 | METHOD FOR PRODUCING ORGANIC MATERIAL MICROPARTICLES, AND METHOD FOR MODIFYING ORGANIC MATERIAL MICROPARTICLES - Provided are a method for producing organic material microparticles and a method for modifying organic material microparticles, whereby it becomes possible to improve the crystallinity of organic material microparticles or achieve the crystal transformation of the organic material microparticles while preventing the growth of the organic material microparticles in a solvent. A surfactant is added to a solvent that is capable of partially dissolving organic material microparticles, and then the organic material microparticles are reacted with the solvent. In this manner, it becomes possible to improve the degree of crystallization of the organic material microparticles or achieve the crystal transformation of the organic material microparticles without substantially altering the particle diameters of the organic material microparticles. | 2017-11-30 |
20170340565 | TREATING FUNGAL INFECTION OF THE NAIL UNIT - Described here are various compositions for the delivery active agents, e.g., antifungal agents. The compositions may be beneficial due to the particular release kinetics associated with them. Various locations and methods for placement of the compositions into the tissues of the nail unit, as well as tissues surrounding the nail milt are also described. | 2017-11-30 |
20170340566 | Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same - Dermal delivery compositions are provided. Aspects of the dermal delivery compositions include the presence of active agent-calcium phosphate particle complexes, where these complexes include uniform, rigid, spherical nanoporous calcium phosphate particles associated with one or more active agents. Also provided are methods of using the compositions in active agent delivery applications. | 2017-11-30 |
20170340567 | BIOACTIVE COMPOUNDS PROTECTION METHOD AND COMPOSITIONS CONTAINING THE SAME - The present invention relates to means for protecting bioactive materials in mammalian food or feed formulations used to enhance the health status of mammals. | 2017-11-30 |
20170340568 | DISINTEGRATIVE PARTICLE COMPOSITION INCLUDING PULVERIZED LACTOSE OR GRANULATED LACTOSE - The purpose of the present invention is to provide a new disintegrative particulate composition having an optimal balance between the tablet hardness and disintegrability that are mutually opposing properties, and disintegrating tablets for pharmaceuticals and various kinds of foods comprising said composition. | 2017-11-30 |
20170340569 | Oral Tablet Formulation Consisting Of Fixed Combination Of Rosuvastatin And Ezetimibe For Treatment Of Hyperlipidemia And Cardiovascular Diseases - The present invention is an orally consumed fixed combination formulation of both rosuvastatin and ezetimibe in one tablet that is expected to have the same Area Under Curve as two active ingredients taken together individually orally, and pharmaceutically acceptable additives suitable for the preparation. In preferred embodiments of this invention, the rosuvastatin is in the form of rosuvastatin calcium and the pharmaceutically acceptable additives are selected from diluents, disintegrants, glidants, lubricants, colorants and combinations thereof. | 2017-11-30 |
20170340570 | Controlled Release Dosage Form with Enhanced Pharmacokinetics - The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABA | 2017-11-30 |
20170340571 | COMPOSITION FOR FORMING COMPLEX, COMPLEX FORMED THEREFROM, AND COMPOSITION FOR ORAL INGESTION, CONTAINING SAME - Disclosed are: a composition for forming a complex; a complex formed therefrom; and a composition for oral ingestion, containing the same. The disclosed composition for forming a complex contains a cellulose-based compound, a polyphenolic compound, a gelling agent, and a solvent. | 2017-11-30 |
20170340572 | STABILIZATION OF BETA-HYDROXYISOVALERIC ACID FORMULATIONS IN SOFT GEL CAPSULES - The disclosed are shelf-stable beta-hydroxyisovaleric acid containing soft gel compositions and methods for making such compositions. In certain aspects, disclosed compositions comprise a plant-based capsule shell and a liquid formulation comprising beta-hydroxyisovaleric acid and at least one excipient, wherein the soft gel capsule is shelf-stable. In certain aspects, the excipient is selected from selected from choline salt, betaine, phosphatidylcholine, alpha-glycerophosphocholine, carnitine, adenosine 5′-triphosphate, or a combination thereof. | 2017-11-30 |
20170340573 | RALOXIFENE SPRINKLE COMPOSITION - The present invention relates to a capsule composition of raloxifene comprising multiparticulates comprising a) a core comprising raloxifene, and b) a taste-masking coating present in amount of from about 0.5% to about 50% w/w based on the core weight. | 2017-11-30 |
20170340574 | Immediate Release Abuse Deterrent Liquid Fill Dosage Form - The present disclosure relates to an oral, immediate release, abuse deterrent liquid filled capsule containing polyethylene glycol and at least one active pharmaceutical ingredient susceptible to abuse. The dosage form is abuse deterrent to parenteral administration. The present disclosure also relates to processes of preparing the dosage form. | 2017-11-30 |
20170340575 | METHOD USING POLYETHYLENE GLYCOL TO PREPARE FIBROIN NANO/MICROSPHERES, AND APPLICATION OF METHOD IN CONTROLLED DRUG RELEASE - A method using polyethylene glycol to prepare fibroin nano/microspheres. A fibroin solution having a mass percentage of 1-30% and a polyethylene glycol solution having a mass percentage of 10-60% are first placed in a 4-60° C. environment for 30 minutes, the fibroin protein solution and the polyethylene glycol solution are then mixed, and fibroin nano/microspheres are produced via incubation and centrifugal washing. | 2017-11-30 |
20170340576 | METHOD AND APPARATUS FOR COMPLETING PRESCRIPTION FOR ALLERGEN COCKTAIL WITH PATCH - A method for creating a multi-antigen patch, comprising providing one or more transdermal patch sheets having a plurality of single dose transdermal patches residing thereon, wherein each one of the plurality of single dose transdermal patches includes an antigen at a particular dilution level disposed within a carrier, removing one or more of the plurality of single dose transdermal patches from the one or more transdermal patch sheets, adhering the one or more of the plurality of single dose transdermal patches to a backing, wherein the backing allows for multiple single dose transdermal patches to be adjacently adhered thereon, and covering the plurality of transdermal patches adhered to the backing with a peelable release liner. | 2017-11-30 |
20170340577 | Transdermal Drug Delivery System - A transdermal drug delivery system is provided that includes a drug-in-adhesive matrix layer and a backing layer. The matrix layer includes an active pharmaceutical ingredient, a cross-linked polyvinylpyrrolidone binder, a mesoporous silicon dioxide filler, and a pressure sensitive adhesive, while the backing layer forms an exterior facing-surface of the delivery system. The ratio of the mesoporous silicon dioxide filler to the cross-linked polyvinylpyrrolidone binder ranges from about 1:1 to about 1:8. As a result of the specific components of the matrix layer and the amounts in which they are utilized, the resulting delivery system, which can include a homogeneous dispersion of the active pharmaceutical ingredient in the formulation, is capable of delivering the active pharmaceutical ingredient over a period of up to about 7 days in a generally constant and controlled fashion. Further, the only layer that contemplates the use of an adhesive component is the drug-in-adhesive matrix layer. | 2017-11-30 |
20170340578 | DEVICE FOR THE TRANSDERMAL DELIVERY OF ROTIGOTINE - A transdermal delivery system (TDS) for the transdermal administration of rotigotine, comprising an adhesive matrix layer, a backing film and release liner, wherein the adhesive matrix comprises rotigotine, an adhesive polymer and a copolymer of polyethylene glycol, polyvinyl caprolactam and polyvinyl acetate. Preferentially, the adhesive polymer is the block styrene-isoprene-styrene (SIS). | 2017-11-30 |
20170340579 | TRANSDERMAL DELIVERY SYSTEM - A transdermal delivery system comprising a drug-containing matrix layer, a release liner and a backing layer. The drug-containing matrix layer further comprises a methylphenidate base, an adhesive polymer made up of a styrene rubber block copolymer having a styrene content of 24% or above by weight of the adhesive polymer; the adhesive polymer is present in an amount of 20% to 45% by weight of the drug-containing matrix layer, a tackifier present in an amount of 30% to 45% by weight of the drug-containing matrix layer, and a hydrocarbon plasticizer present in an amount of 1% to 30% by weight of the drug-containing matrix layer. | 2017-11-30 |
20170340580 | BIOADHESIVE PATCH - A moist, layered bioadhesive patch includes one or more polymers. A method of producing a monolayered film and a method of drying said film is provided. Additionally, there is provided a method of producing bioadhesive, layered patches by combining layers of the monolayered film to obtain a desired thickness of the patch. Patches according to the invention may be used as such, or for delivering pharmaceutically active compounds, such as in a drug delivery system. | 2017-11-30 |
20170340581 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS - A method of treating an ocular disorder in a subject associated with increased all-trans-retinal in an ocular tissue includes administering to the subject a therapeutically effective amount of a primary amine compound of formula (I); and pharmaceutically acceptable salts thereof. | 2017-11-30 |
20170340582 | COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER - The invention relates to the field of prevention and treatment of cancer, in particular suppression of tumor manifestation. The invention also relates to compounds for use in this field. A novel tumour manifestation suppression (TMS) regulation in a mammalian brain is recognized. The invention relates to compounds, pharmaceutical preparations, in particular medicaments for use in the prevention and treatment of cancer, in particular suppression of tumor manifestation based on said TMS regulation as well as methods for the same. | 2017-11-30 |
20170340583 | CAPSULE DOSAGE FORM OF METOPROLOL SUCCINATE - This disclosure provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units, wherein said capsule dosage form is bioequivalent to the marketed Toprol-XL® tablet. The extended-release capsule dosage form comprising coated discrete units can be sprinkled onto food to ease administration to patients who have difficulty swallowing tablets or capsules. | 2017-11-30 |
20170340584 | MODIFIED TAURINE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES CONTAINING SAME - The present invention relates to a modified taurine, and a pharmaceutical composition for preventing or treating metabolic disease or a food composition, which contains the modified taurine as an active ingredient. More specifically, the modified taurine of the present invention has physical properties different from those of existing taurine, and has significant effects on the prevention and treatment of metabolic syndrome, including antithrombotic effects. | 2017-11-30 |
20170340585 | ANTISEPTIC SOLUTIONS AND APPLICATORS - An antiseptic solution comprising a pH-dependent antimicrobial agent, the pH-dependent antimicrobial agent having an operative pH range, wherein the solution has a pH on storage that is lower than the operative pH range. Applicators for applying the antiseptic solution and methods of using the antiseptic solution and applicators are also provided. | 2017-11-30 |
20170340586 | THERAPEUTIC AGENT FOR SENSORINEURAL HEARING LOSS - An object of the present invention is to provide novel apoptosis inhibitors and therapeutic agents for inner ear hearing impairment. As a pharmaceutical agent for this purpose, biguanide compounds represented by the following structural formula (I) or a rapamycin derivative represented by the following structural formula (II) as an active ingredient is provided: | 2017-11-30 |
20170340587 | N-CARBAMOYLPUTRESCINE TO ENHANCE MUSCLE PROTEIN SYNTHESIS - The present invention relates to the field of food supplement and medicament supporting muscle metabolism, more precisely muscle protein synthesis. In particular, the invention relates to a composition comprising N-carbamoylputrescine (NCP). The invention further relates to the non-therapeutic use of N-carbamoylputrescine (NCP) to enhance muscle protein synthesis in a subject. Moreover, the invention also relates to N-carbamoylputrescine for its use as a medicament. | 2017-11-30 |
20170340588 | MODULATION OF REGULATORY T CELLS VIA G-COUPLED PROTEIN RECEPTOR 43 - Disclosed herein are compositions and methods that are useful for inducing the development of regulatory T cells (T | 2017-11-30 |
20170340589 | Treatment of intrahepatic cholestatic diseases - Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof. | 2017-11-30 |
20170340590 | AQUEOUS ANTIMICROBIAL COMPOSITION - A gel useful in reducing bacterial colonization in or around the area of a wound can be provided by combining at least one PEG with an aqueous composition having a pH of from 2 to 4, a total solute concentration of from 1.8 to 4.0 Osm/L, and from 0.9 to 1.7 g/L of at least one cationic surfactant. The aqueous composition can include a buffer system that includes an organic acid and a salt of an organic acid. The gel is effective even when free of materials having antimicrobial properties other than those provided by the aqueous composition such as sporicides, antifungals and antibiotics. | 2017-11-30 |
20170340591 | ALPHA-CELL RE-GENERATION COMBINED WITH CONVERSION TO BETA CELLS - The present invention relates to methods of generating a population of beta cells from a population of alpha cells, by contacting said population of alpha cells with GABA or a GABA receptor agonist, in combination with a monoclonal glucagon neutralizing antibody or other alpha cell mass regulating compounds, for an improved diabetes therapy. | 2017-11-30 |
20170340592 | Controlled Release Dosage Form - The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABA | 2017-11-30 |
20170340593 | MEDICAMENTS FOR SLOWING PARKINSON'S DISEASE - Opicapone, levodopa and an AADC inhibitor are described for use in slowing the progression of Parkinson's Disease. | 2017-11-30 |
20170340594 | PHARMACEUTICAL COMPOSITIONS FOR TREATING ACNE - The present application relates to pharmaceutical compositions comprising retinoic acid or its derivatives such as isotretinoin and processes for preparing thereof. It also provides methods for treating acne by administering such pharmaceutical composition to a patient in need thereof. | 2017-11-30 |
20170340595 | Compositions and Methods for Treating Autism Spectrum Disorders - The instant disclosure features, among other things, compositions and methods for treating an autism spectrum disorder in a human. The compositions comprise an effective amount of: (1) an isothiocyanate (e.g., sulforaphane or a derivative thereof) or (2) a glucosinolate, and optionally, an enzyme, to thereby treat an autism spectrum disorder and/or reduce the severity of at least one symptom of the disorder. Methods for preparing such compositions are also featured. | 2017-11-30 |
20170340596 | TREATMENT FOR OBESITY - The present invention relates to a method for treating or preventing obesity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. The invention further relates to methods for reducing body weight and/or reducing food intake in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. | 2017-11-30 |
20170340597 | LONG ACTING PHARMACEUTICAL COMPOSITION OF PROTEASE INHIBITOR - Disclosed herein is a long acting pharmaceutical composition for treating or preventing human immunodeficiency virus (HIV) infection. The pharmaceutical composition comprises a suspension of a lysine-based aspartyl protease inhibitor or salt thereof, a surface modifier, and a pharmaceutically acceptable carrier; wherein the lysine-based aspartyl protease inhibitor or salt thereof has an average effective particle size of less than about 500 nm. A method for treating or preventing HIV infection with the pharmaceutical composition is also disclosed. | 2017-11-30 |
20170340598 | Method of Reducing Uric Acid with Fucoxanthin-Containing Composition - The present invention provides a method of reducing uric acid in a subject in need thereof, comprising administering to the subject a composition comprising an effective amount of fucoxanthin, wherein the fucoxanthin has the effect of reducing uric acid and preventing gout. | 2017-11-30 |
20170340599 | BREAST CANCER THERAPY BASED ON HORMONE RECEPTOR STATUS WITH NANOPARTICLES COMPRISING TAXANE - The present invention relates to methods and kits for the treatment of breast cancer based on hormone receptor status of progesterone receptor and estrogen receptor comprising the administration of a taxane alone, in combination with at least one other and other therapeutic agents, as well as other treatment modalities useful in the treatment of breast cancer. In particular, the invention relates to the use of nanoparticles comprising paclitaxel and albumin (such as Abraxane®) either alone or in combination with other chemotherapeutic agents or radiation, which may be used for the treatment of breast cancer which does not express estrogen receptor and/or progesterone receptor. | 2017-11-30 |
20170340600 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT - Embodiments of the present disclosure provide for compositions including an antimicrobial agent, pharmaceutical compositions including the composition or pharmaceutical composition, methods of treating a condition or disease, methods of treatment using compositions or pharmaceutical compositions, and the like. | 2017-11-30 |
20170340601 | Composition for Prevention or Treatment of Cutaneous Disorder - The present invention relates to a pharmaceutical composition or medical device comprising a fucoidan and at least one compound of formula A or B: | 2017-11-30 |
20170340603 | COMPOSITIONS AND METHODS FOR SKIN CARE - Compositions and methods are for disclosed for treating a skin condition that results from reactive oxygen species production in skin of a subject, including applying a topical formulation that contains a lipophilic cation-mitochondrially targeted antioxidant compound and that delivers a therapeutically effective amount of the antioxidant compound to skin fibroblasts and keratinocytes. | 2017-11-30 |
20170340604 | THERAPEUTIC COMPOUNDS AND USES THEREOF - The present invention relates to compounds of formula (I): | 2017-11-30 |
20170340605 | THERAPEUTIC COMPOUNDS AND USES THEREOF - The present invention relates to compounds of formula (I): | 2017-11-30 |
20170340606 | METHODS OF TREATING MUSCULAR DYSTROPHY - Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed. | 2017-11-30 |
20170340607 | ANTIFUNGAL AGENTS - The invention provides a pyrrole compound, which compound is (a) 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoacetamideor a deuterated derivative thereof, or (b) 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)-3-hydroxyphenyl)-2-oxoacetamide or a deuterated derivative thereof, or (c) a prodrug of compound (a) or a prodrug of compound (b), or a pharmaceutically acceptable salt or agriculturally acceptable salt of (a), (b) or (c). Also provided are combinations and compositions comprising the compound and known antifungal agents. The invention also relates to the therapeutic use of a compound of the invention in prevention or treatment of fungal diseases. It also relates to the use of: 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoacetamide or an agriculturally acceptable salt thereof, or 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)-3-hydroxyphenyl)-2-oxoacetamide or an agriculturally acceptable salt thereof, as an agricultural fungicide. | 2017-11-30 |
20170340608 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions - Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of proteins and thereby decreasing aggregate formation by these proteins. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein. | 2017-11-30 |
20170340609 | ANTIMICROBIAL AGENTS AND THE METHOD OF SYNTHESIZING THE ANTIMICROBIAL AGENTS - New 1,3-dipenyl pyrazole derived azomethines and N-aryl amines have been synthesized. These anti-MRSA agents combat MRSA and other infections. These azomethine and N-arylamine derivatives of benzoic acid provide combat MRSA and other infections. | 2017-11-30 |
20170340610 | RORgammaT INHIBITORS - The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition. | 2017-11-30 |
20170340611 | NOVEL COMPOUNDS - Pyrazolone derivatives of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of diseases or conditions in which HNE is implicated. | 2017-11-30 |
20170340612 | TREATMENT FOR CUTANEOUS T CELL LYMPHOMA - The present invention provides method for treating a patient with cutaneous T cell lymphoma (CTCL). Generally, the methods include administering to the patient an IRM compound in an amount effective to ameliorate at least one symptom or clinical sign of CTCL. In some embodiments, the methods also include administering to the patient a priming dose of a Type I interferon. In another aspect, the invention provides methods of increasing a cell-mediated immune response of a cell population that includes cells affected by cutaneous T cell lymphoma. Generally, the methods include contacting the cell population with an IRM compound in an amount effective to increase at least one cell-mediated immune activity of the cell population. In some embodiments, the methods include contacting the cell population with a priming dose of a Type I interferon. | 2017-11-30 |
20170340613 | Novel Imidazole-Based Heterocyclic Compounds - The present invention relates to novel compounds of formula (I) suitable e.g. as therapeutic agents for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes. The present invention also relates to processes for making said agents. | 2017-11-30 |
20170340614 | Compositions and Methods of Treating Muscular Dystrophy with Thromboxane-A2 Receptor Antagonists - The present invention is directed to methods of treating and/or ameliorating muscular dystrophy and/or treating cardiomyopathy in muscular dystrophy patients by administration of a therapeutically effective amount of a thromboxane A | 2017-11-30 |
20170340615 | COMPOSITIONS, METHODS AND KITS FOR REDUCING LIPID LEVELS - Compositions, methods, and kits useful for treating hyperlipidemic conditions are provided herein. Such compositions can contain synergizing amounts of nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites in combination with leucine and/or a leucine metabolite, with or without resveratrol. | 2017-11-30 |
20170340616 | AMINOESTER DERIVATIVES - Compounds of formula (I), defined herein, are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract. | 2017-11-30 |
20170340617 | PYRIDONE DERIVATIVES AS REARRANGED DURING TRANSFECTION (RET) KINASE INHIBITORS - This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity. | 2017-11-30 |
20170340618 | 2-Amino-5,5-Difluoro-6-(Fluoromethyl)-6-Phenyl-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors - The present invention is directed to compounds of Formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Aβ deposits is beneficial such as Alzheimer's disease. | 2017-11-30 |
20170340619 | METHODS OF TREATING BEHAVIORAL SYNDROMES USING PIPRADROL - Methods of treating behavioral syndromes by administering a pharmaceutical composition of pipradrol or a pharmaceutically acceptable salt thereof are provided. The methods may be used to treat Attention-Deficit Disorder (ADD) and Attention-Deficit Hyperactivity Disorder (ADHD). | 2017-11-30 |
20170340621 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS - The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, n, W, X, Y, Z, R | 2017-11-30 |